Category: Lanx Inc.
Stryker (NYSE:SYK) CEO Kevin Lobo told an investors conference audience in Las Vegas yesterday that the medical device company is still in the mergers & acquisitions hunt, even after its newsmaking buyouts of China's Trauson Holdings, Israel's Orthovita and Surpass Medical.
A Delaware state court rules that NuVasive can review documents covering current and former employees' contacts with Lanx, which NuVasive accuses of poaching its talent.
NuVasive Inc. (NSDQ:NUVA) can review documents covering Lanx Inc.'s contacts with current and former NUVA employees it alleges were poached by Lanx.
NuVasive's ongoing legal battle with Lanx Inc. over the defection of a slew of its former sales reps continues with a lawsuit filed against 3 former reps in New York.
NuVasive Inc. (NSDQ:NUVA) opened another front in its ongoing war with rival Lanx Inc., accusing 3 former sales reps of defecting to Lanx and taking trade secrets with them.
Lanx Inc. loses its bid to toss a breach-of-contract lawsuit filed against it by competitor NuVasive, alleging that Lanx raided its national sales force.
Medical device company Lanx Inc. lost a bid to have 1 of at least 2 breach-of-contract lawsuits filed against it by competitor NuVasive (NSDQ:NUVA) thrown out.
Following his resignation from the top job at Stryker, Stephen MacMillan also drops his seat on the Texas Instruments board.
Following his abrupt resignation from the corner office at Stryker Corp. (NYSE:SYK), Stephen MacMillan also stepped down from the Texas Instruments board of directors.
MacMillan had been on the board since 2008. No reason was given for his departure in regulatory filings.
BG Medicine taps industry veteran and former BioMérieux exec Eric Bouvier as its new president & CEO.
Eric Bouvier took over the corner office at BG Medicine (NSDQ:BGMD) yesterday as president & CEO of the Waltham, Mass.-based diagnostics developer.
Prior to joining BG, Bouvier, 51, headed the Immunoassay business at global diagnostics company BioMérieux. He also held the role of president & CEO of BioMérieux's U.S. subsidiary bioMerieux Inc.
Nevro Corp. closes $58 million financing round to fund U.S. pivotal trial of spinal cord stimulation system for pain management.
Nevro Corp., an early stage company that makes a spinal cord stimulator for chronic pain, has raised $58 million to continue development of its flagship product and prepare for a possible U.S. launch.
The Menlo Park, Calif.-based company said the funding round was led by Johnson & Johnson Development Corp. (NYSE: JNJ), along with existing investors Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners.